Evommune, Inc.
EVMN · XNYSCIK 2044725fmd_0XXG64J0ZXR005N7RPSTT4ZE4YManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2024 to Sep 30, 2026, 9 periods
| Line item | FY2024 | FY2025 |
|---|---|---|
| Total revenues | 7 | 13 |
| Research and development | 64 | 74 |
| Total operating expenses | 77 | 94 |
| Operating income | (70) | (81) |
| Interest and investment income | 3 | 3 |
| Other non-operating income (expense) | 3 | 12 |
| Income before taxes | (68) | (69) |
| Income tax expense | 0 | 0 |
| Net income from continuing operations | (68) | (69) |
| Net income | (67) | (69) |
| Net income to common shareholders | (68) | (69) |